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Abstract: The primary role of the immune system is to protect the organism against pathogens, 
but age-associated alterations to immunity increase the susceptibility of the elderly to infec-
tious disease. The exact nature of these changes is still controversial, but the use of screening 
procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better 
characterize the changes actually related to physiological aging rather than pathology. It is 
generally agreed that the most marked changes occur in the cellular immune response reﬂ  ect-
ing profound alterations in T cells. Much of this is due to thymic involution as well as changes 
in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell 
activation pathways. However, a body of data indicates that innate immune responses, includ-
ing the critical bridge between innate and adaptive immunity, and antigen presenting capacity 
are not completely resistant to senescence processes. The consequences of all these alterations 
are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, 
and chronic inﬂ  ammatory diseases. The leading question is what, if anything, can we do to 
prevent these deleterious changes without dangerously dysregulating the precarious balance 
of productive immunity versus immunopathology? There are many potential new therapeutic 
means now available to modulate immunosenescence and many others are expected to be 
available shortly. One main problem in applying these experimental therapies is ethical: there 
is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do 
not require adventurous therapies with unpredictable side-effects in mostly frail individuals. 
Animal models are not helpful in this context. In this chapter we will ﬁ  rst brieﬂ  y review what 
we think we know about human immunosenescence and its consequences for the health status 
of elderly individuals. We will then discuss possible interventions that might one day become 
applicable in an appropriate ethical environment.
Keywords: immunosenescence, T cells, phagocytic cells, nutrition, vaccination, exercise, CMV, 
inﬂ  ammaging, IRP, immunorestorative therapies
Immunosenescence
As human beings reach ever older average and maximal ages, the emergence of many 
diseases associated with aging becomes more apparent. The incidence of infections, 
cancers, and chronic inﬂ  ammatory diseases such as atherosclerosis and neurodegen-
erative diseases increases with age (Wick et al 2000). Although we still do not know 
what is the exact cause of aging; we recognize that changes of the immune system play 
an important role both in the aging process and in the increase of age-related diseases 
(Meyer 2005). The immune system is a complex interactive system composed of many 
different players that are not all altered in the same manner and do not contribute 
equally to aging. We should perhaps conceptualize immunosenescence as dysregula-
tion of a homeostatically constantly adapting system, the inputs and outputs of which 
are still only crudely deﬁ  ned, let alone the pathways linking these (Pawelec 2003). 
At the whole organism level, many studies have documented changes in endocrine 
and neural function, cardiovascular, muscle, and skeletal health, as well as regulation 
of glucose metabolism (Kyriazis 2005). It must be borne in mind that these diverse 
physiological changes also affect the immune system, although very few investigations Clinical Interventions in Aging 2007:2(1) 34
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address these issues, especially in humans. Although nu-
merous studies on age-associated immune alterations exist 
(collectively known as “immunosenescence”) (Miller 1996; 
Pawelec and Solana 1997), the exact nature of these is still 
controversial because of differences between species, the lack 
of deﬁ  nition of physiological aging rendering difﬁ  cult the 
exclusion of some latent disease states, nutritional, genetic, 
and environmental differences, amongst other factors 
(Ligthart 2001). However, the clinical consequences of the 
decreased immune response with aging seem quite clear. 
These are mainly the increased incidence and severity of 
infections, and possibly also cancers and autoimmune disor-
ders (Meyer 2005). Many elderly subjects actually die from 
infections even if the cause of death given by the attending 
physician is very different. The hallmark of immunosenes-
cence is the overwhelming decrease in T cell function with 
aging (Vasto et al 2006). There are also changes in the other 
parts of the immune system, but they are much less marked, 
and may often be secondary to changes in the T cells (not 
only the T cell-dependent B cells, but also innate components 
sensitive to T cell feedback, especially antigen-presenting 
cells [APC]) (Figure 1). Such age-related changes of the 
immune response are multifactorial, but it is reasonable to 
think that the extra-cellular milieu is very important.
Effects of the aging environment
on the immune system
Cells of the adaptive immune system may be affected by 
nonspeciﬁ  c sequels of the aging process such as oxidative 
stress or glycation (Pahlavani and Harris 1998; Poggioli 
et al 2004). The former, resulting from an imbalance between 
the production of free radicals and antioxidant defences, is a 
characteristic of the aging process and may affect immune 
cells. The most susceptible molecules are DNA, proteins, and 
lipids. Indeed, DNA damage increases and repair decreases in 
lymphocytes with aging (Pawelec 2000). Alterations in lipids 
may lead to an increase of oxidised lipid products in the cell 
membrane such as 7-keto cholesterol which could interfere 
with effective lipid raft functioning in the membrane. The 
protein alterations induced by free radicals interfere with 
their functions and may compromise enzyme activity. The 
clearance of these modiﬁ  ed proteins by molecules such as 
methionine sulfoxide reductases A (MrsA) is altered with 
aging (Petropoulos and Friguet 2005). The formation of 
advanced glycation end products (AGE) can alter cell func-
tions and cause a constant inappropriate cellular stimulation 
with resulting telomere shortening. Together these nonspe-
ciﬁ  c changes could contribute to a cellular stress response 
resulting in the low grade inﬂ  ammation commonly observed 
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Figure 1 The immune system in the elderly. The function and parameters which change during aging are summarized in this ﬁ  gure. 
Abbreviations: CMV, cytomegalovirus; DISC, death-inducing signaling complex; IL-2, interleukin-2; KLRG-1, killer cell lectin-like receptor subfamily G member 1; NF-AT, 
nuclear factor of activated T cells; NF-κB, nuclear factor κB; MAPK, mitogen-activated protein kinase; PKC, protein kinase C, TCR, T cell receptor.Clinical Interventions in Aging 2007:2(1) 35
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in aged individuals. Finally, the role of protein-energy mal-
nutrition (PEM) may be relevant, because as many as 5% of 
free living elderly suffer from PEM. This percentage is much 
higher (up to 50%) in hospitalized or frail elderly subjects. 
PEM is a general immunosuppressant, causing a decrease 
in delayed-type hypersensitivity (DTH), interleukin (IL)-
2 production, and T cell proliferation as well as antibody 
responses (Lesourd 1997, 1999). Of course, this decrease 
in immune responses due to PEM may be relatively eas-
ily corrected by nutritional supplementation (High 2001). 
Among the necessary micronutrients required in addition 
to protein supplementation, the most studied has been zinc 
(Mocchegiani et al 2000a). Zinc deﬁ  ciency has been linked 
to profound effects on cell-mediated and humoral responses. 
Malnutrition, via T cell function alteration, is a major risk 
factor for infections. Moreover, infections themselves induce 
malnutrition and generate a vicious circle between malnu-
trition and infection. One of the mechanisms induced by 
reactive oxygen species is DNA damage, particularly at the 
mitochondria level. Indeed such damage leads to decreased 
adenosine triphosphate (ATP) formation with ageing. In 
consequence, nutritional requirements are increased to 
compensate for this lack of ATP (Voorips et al 1993). This 
cannot compensate properly for mitochondrial inefﬁ  cacy 
(Roberts et al 1994).
Adaptive immune system
Thymic involution
The thymus is the central organ for T cell maturation 
(Rubin and Kretz-Rommel 2001). Thus, from the outset, 
much attention was focused on the thymus as responsible 
for the defective production of naïve T cells, ie, those able 
to respond to newly encountered antigen, via alterations 
in the induction of their maturation and differentiation, as 
well as in the well-established reduction in their numerical 
output (Aspinall 2000). Experimental data in animals and 
humans clearly showed that age-associated involution of the 
thymus precedes the failure of T cell functions (Hirokawa 
and Utsuyama 1989; Fagnoni et al 2000). This leads to the 
explanation that thymic involution could be of major inﬂ  u-
ence in immunosenescence. It is of note that the exact cause 
of this age-associated thymic involution is still not known 
although many parameters such as the hormonal status are 
involved (Hadden 1998). Unlike age-associated involution, 
thymic involution caused by stress, or pregnancy seems 
completely reversible (Rijhsinghani et al 1996). However, 
recent studies have shown that even the involuted thymus of 
probably most elderly people is still able to produce naïve 
T cells albeit at much reduced levels (Berzins et al 1998). 
Manipulations for prevention or reversing thymic involu-
tion including insertion of a transgene for a complete T cell 
receptor (TCR) (Lacorrazza et al 1999) or Fas, as well as 
extra-thymic factors such as zinc, melatonin, IL-7, and thy-
roid hormones have been explored and sporadically reported 
to be effective in certain animal models (Virts et al 2006). 
These still controversial interventions will be discussed in 
greater detail later in this chapter.
Phenotype changes: role of continuous 
antigenic stimulation 
Paralleling thymic involution, a change in peripheral T cell 
subpopulations is found in aging (Effros 2004). The number 
of naïve T cells decreases, while memory T cells increase. 
Many expansions of these memory T cells are within the 
CD8+ T cell subset, which are mostly negative for the impor-
tant monomorphic T cell costimulator CD28 (Vallejo et al 
1999). Moreover, these CD8+ memory T cells have shortened 
telomeres, suggesting an extensive replicative history. The 
loss of the CD28 co-receptor provides an explanation for the 
telomere shortening and proliferation arrest because signaling 
via this molecule is essential for telomerase induction and 
prevention of telomere shortening (Pawelec 2000). These 
cells may be in a replicatively senescent state in accordance 
with Hayﬂ  ick’s limit (Effros and Pawelec 1997). They 
may ﬁ  ll the “immunological space” without being able to 
proliferate, to secrete IL-2 or to die by apoptosis. This leads 
to an alteration of T cell-mediated and T cell-dependent 
functions. Many of these CD8+ T cells in humans are found 
to carry receptors for cytomegalovirus (CMV) antigens 
(Khan et al 2002; Ouyang et al 2003). Because almost all 
of the elderly individuals during their life encounter many 
antigens, usually of infectious origin, but conceivably also 
cancer antigens, continuous antigenic stress exhausts the 
immune system and creates cells possessing a phenotype of 
replicative senescence. During normal ageing, accumula-
tions of such “exhausted” T cells predominantly speciﬁ  c 
for persistent Herpes viruses occur (not only CMV, but also 
Epstein-Barr virus [EBV] and possibly herpes simplex virus 
[HSV]). These cells, mostly CD8+ T cells, but also some 
CD4+ T cells, commonly express inhibitory receptors such 
as the recently-described killer cell lectin-like receptor G1 
(KLRG-1) (Ouyang et al 2003). Thus, the reason for much 
of this shift in T cell subpopulations towards CD8+ T cells 
terminally-differentiated memory cells may be infectious 
(Pawelec et al 2004).Clinical Interventions in Aging 2007:2(1) 36
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Profound age-related changes occur also in the CD4+ T 
cell compartment, whether at rest or during activation. CD4+ 
T cells also require CD28 for adequate activation; with aging, 
the proportion of CD4+ cells expressing little or no CD28 
increases signiﬁ  cantly, along with telomere shortening in 
both CD4+ CD28- and CD4+ CD28+ populations (Valenzuela 
and Effros 2002). Other marked changes occur in CD4+ sub-
populations as well, both in terms of the percentage of cells 
expressing a certain molecule, and the density of expression 
of that molecule. For example, interestingly, CD4+ CD25+ 
cells with low-level CD4 expression also accumulate in 
the blood of otherwise healthy elderly people (Dejaco et al 
2006). This may parallel the reported age-associated increase 
in suppressive T regulatory cells (Gregg et al 2004). It has been 
shown that decreased levels of CD28 expression is directly 
related to a signiﬁ  cant elongation of “reaction time”, required by 
the CD4+ cells stimulated in vitro before they start ﬁ  rst mitosis 
(Witkowski and Bryl 2004). Interestingly, studies on centenar-
ians did not reveal such a striking shift, suggesting that these 
selected “successfully aged” individuals were genetically and 
epigenetically resistant to these chronic viral infections or the 
exhausting effect of these infections on their immune system 
(Cossarizza et al 1996). Together, these and many other reported 
changes in T cell subpopulations seem to be universal and thus 
far inevitable in that they are present in all individuals, but their 
quantitative differences could contribute to differences in the 
impact of immunosenescence in a major way.
Alterations to T cell activation pathways
T cells need to be activated by an antigen presented by an 
APC (Friedl and Gunzer 2001). The best known of these 
are dendritic cells (DC), although monocytes/macrophages, 
B cells, and neutrophils are also able to present antigens. 
Once the antigens are presented in the context of MHC 
restriction, naive T cells become activated, produce IL-2 
and other cytokines, and enter differentiation pathways 
resulting in the development of different T cell subsets, 
according to the priming conditions (Nel and Slaughter 
2002). A universal requirement for any T cell response is 
marked proliferation to accomplish the clonal expansion 
critical for generating sufﬁ  cient T cells to combat the source 
of antigen. Thereafter, controlled cell death (apoptosis) 
restores the numerical balance in the immune system, 
but results in the retention of memory T cells competent 
to respond more effectively to rechallenge by the same 
pathogen. Memory T cells possess different stimulatory 
requirements than naïve T cells, but both naïve and memory 
cells respond less effectively with age.
The primary receptor for T cell activation is the antigen-
speciﬁ  c TCR which delivers “signal 1”. However, this is not 
sufﬁ  cient for full activation, and to avoid anergy induction, 
the T cell requires a second signal, delivered by co-receptors 
(Nel and Slaughter 2002). Functionally the most important 
of these is designated CD28, which delivers the second sig-
nal for sustaining T cell activation (Riley and June 2005). 
In addition, activation via CD28 is very important for re-
expression of the TCR, for the recruitment and stabilization 
of T cell lipid rafts to the “immunological synapse” and for 
the stimulation of the phosphoinositide kinase-3 (PI3K) 
signaling pathway (Tavano et al 2004). Furthermore, CD28 
co-stimulation synergizes with TCR activation and induces 
IL-2, IL-4, IL-5, tumor necrosis factor (TNF), and granu-
locyte macrophage colony-stimulating factor production 
via nuclear factor-kappa B (NF-κB) activation (Wang et al 
2004). More co-stimulation is required for the activation of 
naïve cells than for memory cells. Moreover, the activation 
of CD28 protects T cells from activation-induced cell death 
(AICD) (Borthwick et al 2000). It is now well-established 
that CD28 expression is decreased with aging in both CD8+ 
and CD4+ lymphocytes; however this affects more the CD8+ 
T cells (Larbi, Dupuis, et al 2006). This diminution of CD28 
signaling can contribute to the decrease of telomerase up-
regulation as well as to decreased IL-2 production, leading 
to decreased or delayed proliferation (Kaltoft 1998). Thus, 
changes either in co-receptor number or signal transduction 
could have far-reaching effects on T cell functions with 
aging including decreased proliferative responses. It is very 
important that in addition to providing the second signal, 
CD28 is also responsible for the activation of the cellular 
metabolism of proteins, lipids, and carbohydrates (Kane and 
Weiss 2003). Counterbalancing activatory costimulators such 
as CD28, there are also inhibitory co-receptors, such as the 
CD28-related cytotoxic T-lymphocyte-associated antigen-
4 (CTLA-4), amongst others. Changing relative levels of 
activatory and inhibitory receptors with age are likely to 
inﬂ  uence T cell activation.
Activation is the result of the formation of an immune 
synapse between the APC and the T cell via the recruitment 
of lipid rafts. Lipid rafts are membrane microdomains which 
are by their structures specialized in signal transduction 
(Simons and Ikonen 1997). They are mainly composed of 
cholesterol, sphyngolipids, and lipidated signaling molecules. 
Their coalescence (“lipid rafting”) is essential for signal 
transduction. Following their coalescence the molecule Lck 
is autophosphorylated, activating ZAP-70 and leading to 
the activation of linker of activated T cells (LAT). LAT is Clinical Interventions in Aging 2007:2(1) 37
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a transducing signaling molecule platform. From this point, 
several other signaling pathways are activated such the protein 
kinase C (PKC), mitogen activated protein kinases (MAPKs), 
and PI3K (He et al 2005). The decline in these signaling path-
ways leads to a decrease in transcription factors in T cells such 
as NF-κB and nuclear factor of activated T cells (NF-AT). 
NF-κB regulates the expression of many cytokines including 
IL-1, IL-2, IL-6, IL-8, TNF-α, and adhesion molecules (Wang 
et al 2004). These signaling pathways converge to assure an 
appropriate activation of T cells (He et al 2005).
There are several age-associated alterations in these 
T cell activation pathways, as has been shown in experimental 
animals (Sadighi and Miller 2005) and humans (Fulop et al 
2005). The most important changes occur in CD4+ T cells 
resulting in the decreased production of IL-2 and clonal 
expansion (Schindowski et al 2002). There are no changes 
in TCR number at the cell surface, but the number of CD28 
molecules decreases with aging (Vallejo et al 1999). Thus, 
although the antigen receptor numbers do not decrease, their 
functions are altered. Almost all molecules of the signaling 
pathways elicited by TCR or IL-2R were found to be altered 
in T cells with aging (Pawelec et al 2001; Larbi, Douziech, 
et al 2004). There is a decrease in the early tyrosine phos-
phorylation and generation of second messengers, calcium 
mobilization, and the translocation to the membrane of PKC. 
The intermediate steps of the signaling pathways including 
Raf-Ras-MAPKs activation are also decreased. This decline 
of transmembrane signaling leads to the decreased activa-
tion of transcription factors, especially NF-κB and NF-AT 
(Pahlavani et al 1995; Ponnappan, Trebilcock, et al 1999; 
Ponnappan, Zhong, et al 1999). As these factors play a cru-
cial role in the expression of genes involved in the immune 
response, their decrease leads to the altered production of 
cytokines with aging in T cells. These are mainly IL-2, 
IL-6, and TNF-α (Rink et al 1998). Investigations in the 
late 80’s already suggested that biochemical and biophysical 
alterations of the cell membrane could be responsible for the 
altered immune response with aging (Maczek et al 1998). 
Alterations in the lipid composition and ﬂ  uidity of the cell 
membrane were found. The situation was further clariﬁ  ed by 
the discovery of lipid rafts (Simons and Ikonen 1997; Laude 
and Prior 2004). As mentioned above, both the composition 
and function of lipid rafts are critical for T cell activation 
(Taner et al 2004). Cholesterol, the major stabilizing com-
ponent of lipid rafts, is increased two-fold with aging and 
this effectively renders the membrane less ﬂ  uid or more rigid 
(Larbi, Dupuis, et al 2004; Larbi, Douziech, et al 2004). This 
decreases the possibility of recruiting signaling molecules 
such as Lck and LAT, resulting in impaired coalescence and 
altered immune synapse formation. Recently, a group led 
by Miller showed that CD4+ T cells from old mice, which 
are the most affected by the aging process, have defects in 
their activation process and a deﬁ  ciency in the formation of 
immunosynapses during stimulation by antigen-presenting 
cells. They showed that CD4+ T cells from old mice express 
unusually high levels of glycosylated forms of the T cell 
glycoprotein CD43, particularly on a subset of functionally 
anergic cells expressing P-glycoprotein. T cells from old 
mice also show a decline in the association of CD43 with 
cytoskeletal matrix and in the proportion of T cells that can 
exclude CD43 from the synapse (Garcia and Miller 2003; 
Garcia et al 2005). These data support the idea that changes 
in T cell surface glycosylation could play an important role 
in immunosenescence. Currently we do not know why this 
alteration of the membrane occurs with aging. An intrinsic 
alteration of cholesterol metabolism in the elderly could 
contribute to these lipid changes (Simons and Ikonen 2000). 
Thus, an alteration in the membrane composition of T cells 
with aging seems to play a fundamental role in their decreased 
functions and as such in immunosenescence.
Recently, the role of counter-activating tyrosine and 
serine/threonine phosphatases was investigated in T cell 
activation (Hermiston et al 2002). There is more and more 
experimental evidence that the balance between tyrosine 
kinases and phosphatases is essential for the maintenance of 
the resting state and for activation (Hamerman and Lanier 
2006). Only a few data exist concerning phosphatase activ-
ity in T cells with aging. Our own studies using cholesterol 
repletion of T cells from young subjects, being a partial aging 
model of T cells (to mimic the increased T cell membrane 
cholesterol content seen in the elderly) suggested altera-
tions in the phosphatase activities (our unpublished data). 
Furthermore, as alterations have been found concerning Src 
homology domain-containing protein tyrosine phosphatase-1 
(SHP-1) activity in neutrophils (Fortin et al 2006), it can be 
supposed that phosphatase activities might be largely altered 
in T cells with aging as well.
Taken together, it can be concluded that with aging there 
is an alteration in T cell activation due to a dysregulation of 
the intracellular signaling pathways via an alteration of the 
T cell membrane composition leading to altered functions 
such as proliferation and IL-2 production.
Activation-induced T cell death (AICD)
Once clonally-expanded T cells have cleared the source of 
antigen, the majority should die to terminate the immune Clinical Interventions in Aging 2007:2(1) 38
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response (Gupta 2000; Larbi and Fulop 2004). As alluded 
to above, this occurs through apoptosis, which is a tightly 
regulated cellular process, involving several death recep-
tors such as Fas (CD95). There is a ﬁ  ne balance between 
the anti- and pro-apoptotic molecules in T cells, with an 
important contribution from molecules of the Bcl-2 fam-
ily and caspases (Werner et al 2002). The latter are either 
initiators (eg, caspase 8) or executioners (eg, caspases 3, 
7, and 9). Mitochondria are important players in this death 
process. AICD is a major mechanism to avoid the accu-
mulation of superﬂ  uous T cell clonal expansions (Fas et al 
2006). Dysregulation of this essential control mechanism in 
the elderly would be expected to cause many problems. It 
was recently shown that AICD is increased in speciﬁ  c T cell 
subsets including the CD4+ apoptosis-sensitive T-helper 1 
cells (Th1) from old mice, as a direct consequence of their 
decreased levels of CD28-mediated co-stimulation, which 
otherwise may protect stimulated cells from apoptosis (Hsu 
et al 2005). One of the mechanisms by which CD28 signal-
ing protects against apoptosis is by preventing CD95 ligand 
(FasL) up-regulation and by increasing the expression of the 
anti-apoptotic proteins c-FLIP short and Bcl-xL (Kirchoff et 
al 2000). Increased susceptibility of CD4 cells to apoptosis 
may thus contribute to immunosenescence (Pawelec et al 
1996) whereas the reciprocal may be true in CD8 cells. Thus, 
it has been shown that defective Fas-mediated apoptosis is 
one of the major mechanisms associated with the accumula-
tion of senescent CD8+ T cells in very old mice. Decreased 
AICD of CD8+ T cells was found in old mice compared 
with CD4+ T cells which may contribute to the expansion 
of CD8+ T cells at the expense of CD4+ T cells with aging 
(Effros 2004). This decreased apoptosis in CD8+ T cells is 
primarily associated with defects in the up-regulation of FasL 
after activation and a decrease in Fas apoptosis signaling 
(Hsu et al 2001). It is of note that the susceptibility to AICD 
of T cell subsets is differential and dependent not only on 
the expression of CD28 but also on other intracellular and 
extracellular factors, including also aberrant T cell recep-
tor downstream-signaling pathways. These ﬁ  ndings were 
further corroborated by our own studies showing that AICD 
is also delayed in T-lymphocytes from elderly donors by 
impaired Fas expression following stimulation (Larbi, Muti, 
et al 2006). Lipid raft disrupting agents such as methyl-b-
cyclodextrin have also been used to demonstrate that lipid 
rafts play a role in these age-related events of apoptosis 
commitment and resistance. Because Fas did not localize to 
lipid rafts with aging during AICD, in contrast with young 
subjects, we can hypothesize that the formation of the death-
inducing signaling complex (DISC) is also impaired in the 
elderly (Larbi, Muti, et al 2006). In contrast, it was found 
that lymphocytes from elderly humans over-expressed CD95 
at the protein as well as the mRNA level, which induces 
apoptosis in the presence of FasL during AICD (Gupta et al 
2004). Both the density of CD95 expressed on lymphocytes 
as well as the number of CD95+ T cells is progressively in-
creased during the course of aging and reaches the highest 
levels in donors of the sixth through the seventh decades. 
Identical ﬁ  ndings were reported on mitogenic stimulation 
of T cells from elderly subjects. CD95 levels then decrease 
again at greater ages and in the very oldest donors, values 
are the same as those observed in young adults. The decrease 
is mainly due to the loss of CD4+ T cells because of their 
increased sensitivity to apoptosis (Salvioli et al 2003). Not 
only is the expression of CD95 increased with age, but this 
is linked to increased CD95-induced apoptosis as well as to 
constitutive activity of caspase-3 and 8 (Gupta et al 2003). It 
can therefore be concluded that in aging there is a progres-
sive imbalance between the apoptosis of CD4+ and CD8+ 
T cells. As discussed here, T cell activation can also initiate 
their apoptosis. It seems paradoxical that although CD4+
T cells maintain levels of CD28 to a greater extent than CD8+ 
T cells, it is the latter that are more resistant to apoptosis. 
This could, however, be due to defective CD28 signaling in 
CD4+ T cells. In fact, although CD8+ T cells lose their CD28 
co-receptor more readily, they are intrinsically less dependent 
on CD28 for activation than CD4+ T cells (Larbi, Muti, et al 
2006). However, in the elderly, many are in a replicatively 
senescent state, and are correspondingly resistant to apoptosis 
and activation (Gupta et al 2005). Thus, the activation of 
T cell subsets sets the stage for their susceptibility to apop-
tosis. Alterations in apoptosis of T cells may be an important 
mechanism in immunosenescence and related diseases such 
as autoimmunity.
B lymphocytes
There is much less information on the functional changes 
of B lymphocytes with aging. We know that the quantity of 
speciﬁ  c antibodies is decreased (Lazuardi et al 2005). In ad-
dition, changes in antibody speciﬁ  city, isotype, afﬁ  nity, and 
afﬁ  nity maturation have been described in old age (Dailey 
et al 2001; Howard et al 2006). This manifests itself in the 
clinical observation that vaccination in elderly subjects with a 
new antigen such as inﬂ  uenza or tetanus is much less effective 
in terms of resulting speciﬁ  c antibody response compared 
with young subjects, although the perceived problem in 
this context is most likely primarily T cell deﬁ  ciencies. The Clinical Interventions in Aging 2007:2(1) 39
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dysregulation of the humoral immune response leads to the 
production of low-afﬁ  nity immunoglobin M (IgM) antibod-
ies (LeMaoult et al 1997). It has also been shown that the 
B cell repertoire is changed during the aging process. The 
expression of the RAG-1 gene could be a major inﬂ  uence 
(Ben Yehuda et al 1994) in this age-related change. One 
other possibility to explain such age-related decreases in 
antibody responses is the E2A-encoded transcription fac-
tor E47, which regulates many B cell functions including 
class switch recombination and somatic hypermutation, 
and which is altered with ageing (Frasca et al 2005). Thus, 
the age-associated loss of ability to generate an efﬁ  cient 
humoral immune response results in part from reduced B 
cell generation (Banerjee et al 2002). This may in turn ﬁ  ll 
the immunological space with antigen-experienced B cells. 
Since their Ig repertoire is shrunken (to previous antigenic 
stimulation), these cells make a lower response (in quality) 
to new antigenic stimulation (Johnson and Cambier 2004). 
At the same time, the quantity of auto-antibodies (both organ 
speciﬁ  c and nonspeciﬁ  c) increases. During life many self 
proteins become transformed to nonself as result of changes 
to their structure due to free radical-mediated oxidative 
damage or glycation. Thus, these proteins begin to be seen 
as foreign by the immune system and induce the production 
of a new type of auto-antibodies. 
The notion that CD27 is a marker of memory B cells is 
now becoming accepted (Agematsu et al 2000). Signaling 
via CD27 promotes the differentiation of memory B cells to 
immunoglobulin-secreting cells. The proportion of CD27+ 
CD19+ memory B cells is increased whereas the proportion 
of CD27- CD19+ naïve B cells is signiﬁ  cantly decreased 
(Gupta et al 2005). This may cause the reduced antibody 
response to novel antigens. Moreover, it has been shown 
that following B cell receptor stimulation in aged mice the 
cells did not undergo apoptosis to the same extent as in the 
young. This was explained by a higher level of cellular 
FLICE-inhibitory protein (cFLIP) expression that leads to 
procaspase inactivation. Together, this could result in the 
persistence of self and nonself speciﬁ  c B cells (Montes 
et al 2006). This is correlated with the fact that B cell clonal 
expansion persists in old mice along with the appearance of 
B cell lymphomas (Szabo et al 2004).
While reduced proliferative responses in aging is a 
well-known phenomenon (Whisler et al 1991), the signaling 
defects resulting in this in B cells are mainly unknown. For 
instance, PKC activity as well as protein tyrosine kinases 
(PTK) phosphorylation is signiﬁ  cantly reduced in B cells 
from aged donors following Ig stimulation (Whisler and 
Grants 1993). Further studies are needed to understand the 
role of B cell signaling in age-related changes. It is of note 
that dendritic cells were also shown to exhibit age-related 
changes that ultimately lead to decreased B cell response 
(Aydar et al 2003).
Innate immune system
The innate immune response is composed of phagocytic 
cells, natural killer (NK) cells, and the complement system. 
Its role is as the ﬁ  rst barrier to any invaders and to alert the 
adaptive system to intruding pathogens. It provides a very 
efﬁ  cient system to initiate the inﬂ  ammatory process and to 
ﬁ  nish it by the restitutio ad integrum. For many years, the 
consensus was that the innate immune response does not 
change appreciably with aging. However, more sophisticated 
recent analyses indicate that there are age-associated altera-
tions, decreasing either defence capacity or its modulatory 
activity towards adaptive immune responses (Sudeghi et al 
1999; Fulop et al 2004).
Phagocytic cells
The ﬁ  rst cells to arrive at the site of invasion or tissue le-
sions are neutrophils, followed by monocytes. Their main 
functions are chemotaxis, phagocytosis, and the killing of 
the invaders (Mortensen and Zhong 2000). Macrophages kill 
bacteria, viruses, parasites, and tumor cells either directly or 
through the release of various mediators such as IL-1, TNF-
α, and interferon (IFN)-γ. These mediators are able to inﬂ  u-
ence and activate other immune cells (Scapini et al 2000). 
All these activities depend on speciﬁ  c receptors initiating 
various signaling pathways. The chemotaxis is mediated by 
cell adhesion molecules towards a gradient of chemokines. 
Recognition is via toll-like receptors (TLRs) which recognize 
more or less speciﬁ  cally the pathogen associated molecular 
pattern (PAMP) of the aggressors (Medzhitov 2001). Finally, 
effector functions are mediated by the Fc-receptor family 
and complement receptors. It is now accepted that the innate 
immune response not only has direct effector functions, but 
can also inﬂ  uence the adaptive immune response (Medzhitov 
and Janeway 2000).
Experimental results showed that some phagocytic cell 
functions were altered even in healthy SENIEUR elderly (Fu-
lop et al 2001). The most affected functions were chemotaxis 
and intra- and extracellular killing, whereas phagocytosis 
seemed to be conserved with aging. However, these data 
are still controversial even now, with most investigators 
continuing to believe that the innate immune response does 
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that the number of activated CD14dim/CD16bright monocytes is 
increasing with aging (Sudeghi et al 1999). Concomitantly 
the production of proinﬂ  ammatory cytokines IL-1 and IL-6 
is also increasing. Additionally, the tumor cell cytotoxicity 
of monocytes is decreased with aging because of decreased 
free radical production under stimulation (Fulop et al 1984; 
Provinciali and Smorlesi 2005). Similarly, neutrophils were 
shown to mediate decreased cytotoxicity towards tumor, 
bacteria, and yeast cells. Moreover, recently it became evi-
dent that neutrophils may contribute to the modulation of 
the adaptive immune response via their various cytokine and 
chemokine products, and that this is also impaired with aging 
(Scapini et al 2000). Although the number of receptors such 
as TLRs does not seem to change on human neutrophils and 
monocytes, there is clearly an alteration in their activation. 
This contrasts with the decrease of TLR numbers found on 
macrophages of old mice (Boehmer et al 2005). However, in 
both cases the functions of TLRs were found to be altered with 
aging. Ligands for TLR2 are Gram-positive bacteria, while a 
Gram-negative bacterial product, lipopolysaccharide (LPS), 
is a ligand for TLR4; both of them are found on neutrophils. 
The signal transduction pathway initiated by these interac-
tions is mediated initially by an adaptor molecule, MyD88, 
recruiting various serine-threonine kinases, IL-1 receptor-
associated kinases (IRAKs), and ﬁ  nally leading to NF-κB 
translocation (O’Neill 2006). Among IRAK family proteins, 
IRAK-4 and IRAK-1 play major roles in signal transduction 
under LPS stimulation. However, for some TLRs such as 
TLR3, the signal transduction pathway is independent from 
the activation of MyD88  pathway (Yamamoto et al 2002). 
Recently, TLRs were also found to move into lipid rafts on 
cell activation. The displacement of TLRs to lipid rafts in 
neutrophils is deﬁ  cient with aging, leading to an alteration 
of IRAK activation (Fulop et al 2004). This in turn leads to 
the alteration of NF-κB activation and ultimately to altered 
chemokine and cytokine production. Thus, the recognition-
induced activation of phagocytic cells is altered with aging. 
The FcR-dependent killing by neutrophils and monocytes, 
including free radical and protease production, are severely 
impaired with aging. This leads to decreased efﬁ  ciency of 
elimination of the pathogen. Thus, besides reductions in their 
phagocytic activity, all the other activities of these cells are 
also altered with aging (Burns 2004).
Antigen presentation
It is often said that there are few or no age-associated changes 
in the very important initiating and regulatory function of 
APC for the adaptive immune response. However, aging 
may affect the antigen presenting capacity of these cells by 
inﬂ  uencing their antigen processing capacity, the presence of 
costimulatory receptors such as CD80/CD86 on their surface, 
or the levels of cytokines produced in their microenviron-
ment (Miller et al 1994; Donnini et al 2002). Recently, it 
was shown that the proteasome activity which is essential to 
antigen processing is altered with aging (Carrard et al 2002). 
Proteasomes are multi-catalytic enzymes involved in the 
turnover of most cellular proteins and are also responsible 
for generating antigenic peptides. We do not know exactly 
which components of the proteasome are altered with aging, 
either expression, changes in the proteasome subunits or the 
formation of inhibitory molecules. Nevertheless, with aging, 
it seems that the structure and the activity of the proteasome 
is affected (Ponnappan, Zhong, et al 1999). Thus, it can be 
supposed that antigen processing via the degradation of 
the ingested protein is altered with aging. Moreover, very 
recently it has been shown that localized antigen selection 
inﬂ  uenced by TLR4 signaling could impact on the maturation 
of MHC class II complexes (Blander and Medzhitov 2006). 
Moreover, the aging environment is also favorable to the 
premature activation and maturation of DC, for example, due 
to increased levels of TNF-α, oxidative stress, prostaglan-
dins, and IL-6. Moreover, IL-6 can favor the development of 
monocytes into macrophages instead of DC (Chomarat et al 
2000). These cells become mainly inﬂ  ammatory cells and not 
APC, further increasing the inﬂ  ammatory state in aging.
An important alteration affecting APCs is costimulatory 
activity. For effective and sustained T cell activation, the 
co-receptors of T cells must be activated and triggered by 
structures on the APC (Friedl and Gunzer 2001). Alterations 
either in the number or signal transduction capacity of co-
receptors leads to a decreased T cell response. One of the 
most important and well-characterized co-receptors on T cells 
is the CD28 molecule, as already described above. CD28 
interacts with CD80 and CD86 on APC. Probably the num-
bers of major histocompatibility complex (MHC)-II, CD80, 
and CD86 co-receptors on APC do not change appreciably 
with aging, according to most available data. However, little 
data exists concerning changes of other co-receptors such 
as CD40L (CD154) and ICOS, which is a third member, to-
gether with CD152, of the CD28 co-receptor family (Carreno 
and Collins 2002). ICOS may modulate immune responses by 
increasing the secretion of IL-10. Preliminary data indicate 
that with aging there is an increase in ICOS expression on T 
cell clones (Pawelec 2000). Recently, it has been shown that 
LFA-4, an integrin receptor, may also act as a co-stimulatory 
molecule in synergy with CD28. The CD154/CD40 ligand Clinical Interventions in Aging 2007:2(1) 41
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pair also seems to be decreased with ageing. This area also 
requires deeper exploration in the near future for a better 
understanding of immune response changes and the appear-
ance of immune-related diseases with ageing. 
Co-stimulatory activity is also dependent on the pattern 
recognition receptors including the TLRs. As mentioned, 
these TLRs recognize the PAMPs shared by large groups of 
microbial components which result either in the signaling 
of the presence of pathogens to APCs or the processing of 
the pathogens for antigen presentation. In aged mice, the 
expression of TLRs has been shown to decrease (Boehmer 
et al 2005). In contrast, in humans their number was not 
decreased, but their function decreased. These changes, either 
in TLR number in mice or in TLR function in humans have 
important consequences for antigen presentation resulting in 
altered activation of the innate and adaptive immune response 
with aging. TLR stimulation ultimately results in the secre-
tion of proinﬂ  ammatory cytokines which recruit cells of the 
adaptive immune system. That is why the function of TLRs 
is very important not only for an adequate innate response, 
but also for the adaptive immune response.
Apoptosis
The termination of the inﬂ  ammatory process must be tightly 
regulated. This is mediated as in the case of T cells by the 
death of the participating cells via apoptosis. The most studied 
example is the apoptosis of neutrophils (Fulop et al 2004). 
They die spontaneously without proinﬂ  ammatory stimulation; 
however, in the presence of proinﬂ  ammatory stimuli they can 
survive for at least 72 hours. Neutrophils cannot be rescued 
from apoptosis by proinﬂ  ammatory cytokines in the aged as 
opposed to the young. This is probably the result of altered sur-
vival signaling pathways with aging. These speciﬁ  c pathways 
include the janus kinases and signal transducers and activators 
of transcription (Jak/STAT), PI3K, and MAPK pathways 
(Larbi et al 2005; Fortin et al 2006). The signaling alterations 
result in an imbalance of the Bcl-2 pro- and anti-apoptotic 
family members. While the expression of the anti-apoptotic 
molecule Mcl-1 is decreased, that of the pro-apoptotic mol-
ecule Bax is increased. This favours a pro-apoptotic status even 
under proinﬂ  ammatory stimulation (Fulop et al 2002). There is 
also an increase in caspase 3 activity in neutrophils with aging 
(Fortin et al 2006). The underlying mechanisms responsible 
for all these signaling alterations are not fully elucidated.
NK cells
Natural killer cells are also an important part of the innate 
immune system because of their capacity to recognize 
cells altered either as a result of viral infections, oxidative 
modiﬁ  cations, or carcinogenic transformation. Cytotoxic 
effector functions are mediated by granules containing 
granzyme B and perforin. There are clear alterations of NK 
cells and their functions in aging (Borrego et al 1999). These 
changes have mostly been studied and described in old mice 
and much less is known in humans, although age-associated 
increases in numbers of NK cells have often been described, 
together with a decrease of cytotoxicity at the single cell 
level. There are contradictory data concerning NK cell cy-
totoxicity in response to IL-2 or IFNs. Most studies showed 
that these cytokines used alone or in combination elicited 
better NK cytotoxic responses in the elderly than in young 
subjects (Sansoni et al 1993). However, recent data seem to 
support an alteration in the proliferative capacity of NK cells 
stimulated by IL-2, as well as a decrease in CD69 expres-
sion. Signal transduction as assessed by Ca2+ mobilization 
was also found to be altered in NK cells of healthy elderly 
subjects (Borrego et al 1999). Similar contradictory data exist 
for lymphokine-activated killer cells (LAK). NK cells are 
also able to modulate positively or negatively the adaptive 
immune response via secreted products. The production of 
cytokines by resting or activated NK cells such as IFN-γ or 
chemokines such as IL-8 are found to be decreased in healthy 
elderly subjects. 
Thus, phagocytic and NK cells play a crucial role in the 
alteration of the immune response with aging not only by 
presenting intrinsic changes but also by the dysregulation, 
via the APC, of the adaptive immune response. The further 
study of TLRs is expected to unravel many unsuspected 
interactions during immunosenescence. 
Clinical importance
of immunosenescence
The exact consequences of immunosenescence are very 
difﬁ  cult to assess with certitude. However, the clinical 
observations tend to indicate that the alteration of the immune 
response with aging has very serious clinical consequences 
(Figure 2). This deregulated immune response may be 
responsible for the increased incidence of infections, cancers, 
autoimmune disorders, chronic inﬂ  ammatory diseases, as 
well as subsequently decreased longevity (Castle 2000; Wick 
et al 2000; Gavazzi and Krauze 2002; DeVeale et al 2004). 
A direct effect of immunosenescence on infections, cancers, 
and autoimmune disorders can be easily conceptualized and 
many experimental data seem to support this contention. The 
relationship between immunosenescence and the increased 
incidence of infections with aging can be primary. As the Clinical Interventions in Aging 2007:2(1) 42
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number of naïve CD4+ T cells decreases, the possibility of 
mounting an effective adaptive immune response against a 
new pathogen also decreases (Bryl et al 2000, 2004). The 
deregulation of the immune system leads to a general altera-
tion of the T cell response, a decrease in speciﬁ  city and loss of 
memory. In cases of failure to clear tumors, it is hypothesized 
that one reason may be decreased immunosurveillance. This 
idea is derived from the ﬁ  ndings that tumor regression was 
observed in immunocompetent hosts while cancer incidence 
increased in immunocompromised hosts (Salih and Nussler 
2001). Nevertheless, it is still an important challenge to be 
able to link the age-related increase of cancers to decreased 
immune responses. This would mean that the modulation 
of the dysregulated immune response with aging could 
have some inﬂ  uence on cancer occurrence (Pawelec, Koch, 
Griessemann, et al 2006). Recently, it has been shown that 
the increased tumor incidence with aging was associated 
with decreased cytotoxic T lymphocytes (CTL) activity 
in mice immunized with DCOVA together with an increase 
of NK1.1+CD3+NKT cells suppressing the proliferation of 
T cells (Shi et al 2005). These results may explain why the 
efﬁ  ciency of DC vaccination is decreased in aged mice. 
Moreover, immune parameters speciﬁ  cally related to the age 
of colorectal cancer patients, such as higher levels of C3, C4 
and immunosuppressive acidic protein (IAP), and lower 
T cell stimulation index could contribute to cancer devel-
opment and explain why they respond to a lesser extent to 
adjuvant immunochemotherapy than immunologically intact 
young subjects (Munemoto et al 2004). However, a direct 
demonstration of a causal link between immunosenescence 
and infections or tumors is still missing.
The relationship between immunosenescence and the 
chronic inflammatory processes leading to age-related 
diseases is more difﬁ  cult to understand. However, recent 
reports suggest that changes occurring in immunosenescence 
including the accumulation of anergic CD8+ CD28– cells are 
also observed in diseases such as ischemic heart disease, 
neurodegeneration, and other syndromes (Jonasson et al 
2003). Moreover, the deregulation of cytokine production 
is also observed in these chronic inﬂ  ammatory conditions, 
ie, an increase in proinﬂ  ammatory cytokines such as TNF-α, 
IL-6, and IL-1 as well as an increase of the antiinﬂ  amma-
tory cytokines such as IL-10, IL-4, and IL-15, as posited by 
the Inﬂ  ammAging hypothesis (Franceschi et al 2000b). A 
speciﬁ  c association has been demonstrated between elevated 
TNF-α and dementia (Cacquevel et al 2004). An identical 
association between TNF-α and the endothelial dysfunction 
which is the ﬁ  rst step initiating the atherosclerotic process 
has also been demonstrated (Zhang et al 2006). Vascular wall 
inﬂ  ammation is important in plaque formation, progression, 
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and plaque rupture. Thus, age-related immune deregulation 
associated with chronic inﬂ  ammation and the suppression 
of the adaptive immune response leads to these chronic 
inﬂ  ammatory processes. The increasing prevalence of this 
inﬂ  ammation over decades leads to the development of 
clinically signiﬁ  cant pathological conditions such as cardio-
vascular diseases, dementia, diabetes mellitus, osteoporosis, 
Parkinson’s disease, and arthritis (Tracy 2003). It was also 
demonstrated, albeit in a limited number of subjects, that a 
decrease in T cell functions signiﬁ  cantly correlated with a 
higher mortality after 24 months of follow up in these per-
sons (De Martinis et al 2005). This proinﬂ  ammatory status 
was also linked to the frailty syndrome of elderly subjects 
(Schmaltz et al 2005). This suggests that the decreased T cell 
functions are correlated with a decreased longevity probably 
via the occurrence of life threatening diseases such as infec-
tions and cancer. The chronic inﬂ  ammation has important 
nutritional consequences such as the increased secretion of 
cortisol (Sapolsky et al 1986, 1987) and thus an attrition 
of the muscular mass. This latter is also due to the decrease 
of muscular synthesis from the 5th decade. Muscular attri-
tion is directly linked to the decreased amount of substrate 
for protein synthesis of the immune response which in turn 
leads to a decreased efﬁ  ciency of the immune response. The 
chronic inﬂ  ammation is a result of the persistence of the 
pathogen combined with muscular attrition.
Immune risk phenotype 
If the decrease of the immune response has such devastat-
ing clinical consequences, can we identify immunologi-
cally frail subjects at risk of morbidity and mortality? We 
believe so and have identiﬁ  ed an immune risk phenotype 
(IRP), derived from the OCTO-NONA longitudinal studies 
(Wikby et al 1994; Ferguson et al 1995; Olsson et al 2000). 
The IRP includes increased levels of CD8+ CD28– CD57+ 
cells, CD4:CD8 ratio <1, decreased mitogen-stimulated 
T cell proliferation and CMV seropositivity, suggesting that 
chronic CMV antigen stimulation can drive CD8+ cells into 
a state of replicative senescence, with parallel homeostatic 
decreases in the number of CD4+ cells and CD4/CD8 ratio 
in IRP individuals (Wikby et al 2005). There are also other 
parameters which might be relevant to reﬁ  nement of the IRP 
in future. Possible candidates are cytokines such as IL-6 and 
TNF-α which also predict morbidity and mortality in some 
circumstances. They are already strongly linked to frailty 
in elderly subjects (Ferrucci et al 2002). The measurement 
of C reactive protein (CRP) is also a useful tool since CRP 
synthesis is dependent on IL-6 (Park et al 2005).
Interventions to restore
the dysregulated immune response 
with aging
Having completed the brief wide-ranging survey of age-
associated immune alterations, with emphasis on what is 
known in humans, and having in places alluded to possi-
bilities for therapeutic interventions, we are now ﬁ  nally in 
a position to consider the latter in more detail. So we must 
ask whether immunosenescence is subject to modulation 
and whether effective immunosupportive therapies exist. 
What makes the answer difﬁ  cult to ﬁ  nd in humans is the fact 
that the development of immunosenescence takes decades 
and its clinical manifestations are progressive and could be 
mingled with other manifestations of aging. Moreover, as 
dysregulated immunity predominates in the elderly, it is 
often difﬁ  cult to know which changes are really beneﬁ  cial 
or harmful. Biomarkers of immunosenescence are unreli-
able and therefore monitoring interventions is problematic. 
Nevertheless, considering the alterations and the putative 
causes of immunosenescence, we would suggest that three 
major objectives are emerging: decrease the antigenic load 
either acute or chronic, but especially the latter, with the 
concomitant restoration of changes in T cell subpopulations; 
immunorestoration of the thymic environment to increase the 
naïve cell output; maintain or enhance T cell function (activa-
tion) of remaining intact cells (Figure 3). Some interventions 
can be considered as preventive, such as nutrition and exer-
cise, while others could be curative/supportive in helping to 
circumvent damage already done. It must be clearly stated at 
the outset: no well-established therapy beneﬁ  cially impact-
ing on the very complex nature of immunosenescence is yet 
known due to the absence of knowledge of the real primum 
movens. Nonetheless, we will start with those which could 
have a general preventive effect, and continue with those 
which are more speciﬁ  c for a given alteration.
Overview of possible interventions
It is well known that physical exercise as well as a good 
nutrition is related to a conserved robust immune system 
in aged persons. Hormonal products may also inﬂ  uence 
the activities of the immune system, among which thymic 
peptides and thyroid hormones were shown to modulate and 
even restore deﬁ  cient NK function in old mice. The use of 
some cytokines, such as IL-2, IL-7, IL-12, or IFN-γ, may be 
promising to improve immune cell functions. The use of stem 
cells and thymic reconstitution could have beneﬁ  cial effects 
by restoring the naïve cell compartment. The expansion Clinical Interventions in Aging 2007:2(1) 44
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and banking of autologous T cells for immunorestoration 
purposes is currently under intense investigation. The main-
tenance of telomere length in T cells despite aging could 
help to restore their proliferative capacity. Manipulation of 
lipid metabolism and modulating the cholesterol content 
of T cell membrane could also be helpful. Vaccination for 
eradication of chronic infections might help to reduce anergic 
CD8+ CD28– T cell numbers and increase the naïve CD4+ 
T cell number. Manipulations aimed at selective reduction 
of dysfunctional cells or their restoration to full function 
may be other options.  
Nutrition
It is well accepted that nutrition can inﬂ  uence or even play a 
leading role in the development of various diseases such as 
infections, cancer, and cardiovascular diseases. All these dis-
eases are linked directly or indirectly to the immune response. 
Many studies have therefore been devoted to examining the 
effects of nutrition on the various aspects of the immune 
response in various age-groups and diseases (de Castro and 
Stroebele 2002). Indeed, some of the age-related changes 
considered in our brief survey above could simply reﬂ  ect 
nutritional alterations occurring with aging, the most frequent 
of which is PEM. Even in SENIEUR (Ligthart 2001) and 
nutritionally near-SENIEUR subjects, alterations showing 
nutritional variables contributing to immunosenescence, but 
not explaining all the changes, were identiﬁ  ed (Lesourd 1999; 
Lesourd and Mazari 1999). These results are consistent with 
studies in calorie-restricted rodents which live longer and 
have better immune responses than animals fed adlibitum. 
The use of “functional” foods seems to inﬂ  uence many cel-
lular parameters which can help to decrease the deleterious 
effect of the aging process (Kilara and Panyam, 2003). In 
this context, macronutrients such as antioxidants, dietary 
ﬁ  bre, omega-3 polyunsaturated fatty acids (PUFAs), as 
well as micronutrients such as vitamin E, zinc, iron, copper, 
and selenium are of particular interest (Reinhold et al 1989; 
Mocchegiani et al 2000b; Ahluwalia 2004). Proteins in PEM 
or micronutrients may be of importance, but the equilibrium 
needed between those able to slow down the ageing process 
is still unknown (Lesourd et al 2002). 
Thus, nutritional interventions could be beneﬁ  cial for 
the prevention, retardation or even reversal of established 
immunosenescence. The best example is caloric restriction 
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Figure 3 Preventive/curative strategies to counteract the aging immune system. The strategies depicted are those under current investigation or those proposed in this 
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without undernutrition in animals, which prolongs the 
maximal life span and has beneﬁ  cial effects by maintaining 
a normal immune response even in aged animals. Until now, 
with a very few notable exceptions (Walford et al 2002), this 
intervention could not be implemented and systematically 
studied in humans, but groups of enthusiasts are currently 
performing heroic, some would say foolish, studies on 
themselves. In contrast, large numbers of supplementation 
studies have been performed, and some beneﬁ  cial effects 
in aged individuals have been obtained by using vitamins 
and minerals and/or antioxidants (Lesourd 1997). In Zn-
deprived mice, Zn supplementation led to a normalization of 
thymic architecture and functions (Mocchegiani et al 2004). 
Peripherally, the Zn supplementation was also beneﬁ  cial as 
by increasing T cell and NK cell activities. Zinc and other 
trace elements, such as selenium, showed some beneﬁ  t also 
in elderly subjects by increasing T lymphocyte proliferation 
and DTH (Santos-Neto et al 1992). However, their efﬁ  cacy 
in preventing or reducing morbidity due to immune-related 
pathologies could not be demonstrated in elderly persons 
(Provinciali et al 1998). Of the common vitamins, vitamin E 
has been widely used and has shown several relatively clear 
beneﬁ  cial effects, eg, it restores depressed Th1 responses, 
downregulating prostaglandin E2 synthesis, increasing 
response to inﬂ  uenza vaccination, decreasing oxidative stress 
measured by lipid peroxidation products, and increasing NK 
cell activities (Meydani et al 1997, 2005). It is of note that 
vitamin B12, folic acid, and Zn administered in vivo could 
also beneﬁ  cially inﬂ  uence neutrophil functions (Moroni 
et al 2005). 
Recently, it has been shown that the levels of leptin, a 
peptide hormone, secreted by adipocytes are elevated with 
aging more in men than in women. This may be related 
in some way to the observed loss of appetite evolving to 
anorexia during aging (Di Francesco et al 2006). Moreover, 
this hyperleptinemia associated with PEM can contribute to 
the increased susceptibility to infections via reduced Th1, 
DTH responses and increased TH2 response (Amati et al 
2003). Thus modulation of the leptin levels by nutritional or 
pharmacological interventions could restore the appetite and 
consequently the shift from Th1 to Th2 response.
Lipids could have powerful antiinﬂ  ammatory effects that 
could be used advantageously in combating the low grade 
inﬂ  ammation of aging and in the chronic inﬂ  ammatory 
processes of some age-related diseases such as autoimmune 
diseases, atherosclerosis, or Alzheimer’s disease. One pos-
sibility is using conjugated linoleic acid (CLA). This has 
been shown to have anticarcinogenic, antiatherogenic, and 
antidiabetic properties, correlating with a favorable effect on 
certain aspects of immune function even in healthy humans, 
such as increased lymphocyte proliferation, and decreased 
proinﬂ  ammatory cytokine secretion (Tricon et al 2005). It 
was also shown that it could increase the response to hepatitis 
B vaccination even in the elderly (Albers et al 2003). The n-3 
PUFA have been shown to have potent anti-inﬂ  ammatory 
properties when used as adjuvant therapies in autoimmune 
diseases, osteoporosis and cognitive decline (Fernandes et al 
2003; Calder 2003; Kelley et al 2005). Nevertheless, their 
most important effect is the decrease of the risk and severity 
of cardiovascular diseases originating from atherosclerosis, 
a chronic inﬂ  ammatory condition (Kris-Etherton et al 2003). 
Their activities are related to the modulation of proinﬂ  amma-
tory cytokines. Thus, their use in the prevention or modula-
tion of established immunosenescence could be promising 
and deserves further study.
Lipids can also have an immunomodulating activity 
through their capacity to modulate the membrane micro
environment. The cell membrane is not as homogeneous as 
previously believed, but, as previously mentioned, contains 
lipid rafts enriched in cholesterol, gangliosides, and signal-
ing molecules (Simons and Ikonen 1997). It was shown that 
with aging in various immune cells there is an alteration 
in the membrane ﬂ  uidity rendering these lipid rafts less 
functional (Rivnay et al 1980, Larbi, Douziech, et al 2004). 
Since the 80s, preparations called active lipids (AL 721) 
(Rabinowich et al 1987; Provinciali et al 1990) have been 
used to increase immune cell functions. This has led to some 
success as NK cell activities could be increased in vivo. More 
recently, the use of human high-density lipoprotein (HDL) 
to modulate T cell functions has been tested. This lipid is 
able to extract the accumulated cholesterol from lipid rafts, 
resulting in increased signal transduction via TCR (Duffy 
and Rader 2005). Preliminary results showed that T cell 
proliferation and IL-2 production in T cells of the elderly 
could be enhanced by in vitro administered HDL (Fülöp et 
al unpublished data). More research is needed to establish 
whether the statin-induced decreased low-density lipoprotein 
(LDL) in vivo and corresponding potential HDL increase 
could have similar results. 
Together, data obtained from experimental animals and 
from human studies indicate that appropriate nutrition is 
a powerful but in principle very safe immunorestorative 
means to modulate immunosenescence. However, speciﬁ  c 
supplementation seems only needed where there is a deﬁ  -
ciency resulting in concomitant pathologies. Furthermore, 
each separate intervention has only partial effects as not all Clinical Interventions in Aging 2007:2(1) 46
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immune functions are restored and over-supplementation can 
of course even be harmful (Bogden et al 1990; Chandra 2002; 
Bogden 2004; Stephensen and Kelley 2006). Thus, the best 
way to use nutrition as a modulator of immunosenescence is 
to have an optimal diet from the very beginning throughout 
the entire lifespan, combined with other interventions. In this 
way nutrition could play a real preventive role.  
Exercise
The interaction of physical activity and the immune response 
is very complex (Albers et al 2005). This depends on the cur-
rent status of the immune system as well on the intensity, the 
type, and the frequency of exercise. Nevertheless, exercise 
has been proposed as a potential means to modulate dysregu-
lated immune responses with aging. Although studies have 
resulted in contradictory results, it seems that exercise may 
have some immunorestorative properties on the decreased 
immune response with aging (Kohut and Senchina 2004; 
Smith et al 2004; Kohut et al 2005). Long-term moderate 
exercise may be the best candidate for this purpose. Acute 
and heavy exercise, in contrast, seems to have immunosup-
pressive effects. The beneﬁ  cial effects of exercise have been 
noted for T cell function, antibody production, and macro-
phage responses. Moreover, the imbalance between the Th1 
and Th2 responses in the elderly also beneﬁ  ted, as well as the 
naïve and memory cell imbalance (Karanﬁ  lov et al 1999). 
However, many questions remain to be answered before 
exercise can be considered as a bonaﬁ  de immunorestorative 
intervention in aging. The most important of these is related 
to the intensity and the dose of exercise and to the dura-
tion of the effects. The long-term clinical effects should be 
evaluated by future controlled trials. The identiﬁ  cation of 
the mechanisms by which the appropriate exercise regimen 
exerts beneﬁ  cial effects may help us better understand the 
problems contributing to the immunosenescent state.
Cytokines and hormones
One of the most striking functional alterations observed 
in T cells is the decrease of the production of IL-2. This 
cytokine is essential for the clonal proliferation of anti-
gen-reactive T cells and for antibody production. One 
study was designed to enhance antibody production to 
influenza vaccination using low does IL-2 as an adju-
vant. It was reported that low dose IL-2 treatment was 
an effective means of enhancing the antibody response 
to influenza virus antigens in elderly subjects, without 
serious toxicity (Provinciali et al 1994). Unfortunately, 
there are only a few studies advocating the success of 
such intervention, perhaps solely this one.
Other means to intervene in dysregulated immune 
responses may be by hormonal modulation rather than cyto-
kine application (Arlt and Hewison 2004). It is now accepted 
that the existence of a neuro-endocrine-immune network 
implies that hormonal replacement can have beneﬁ  cial effects 
on immunity in the elderly as well. It seems that estrogen 
can have powerful immunomodulating effects, albeit mainly 
during stress, by modulating the innate immune response 
(Kovacs et al 2004; Kovacs 2005). Another hormone which 
could play an important role in modulating and maintaining 
the immune system is insulin, which can directly inﬂ  uence 
innate immunity via shared signaling pathways involving 
PI3K (DeVeale et al 2004). Thus, insulin resistance devel-
oping with aging even at the level of innate immunity could 
have antiinﬂ  ammatory effects (Pickup and Crook 1998). 
Restoring insulin sensitivity by drugs such as glitazone could 
therefore have a beneﬁ  cial immunorestorative effect in the 
elderly via the modulation of peroxisome proliferator-acti-
vated receptor (PPAR)γ (Berstein et al 2005). Insulin-like 
growth factor-1 (IGF-1) has also been shown to promote 
the survival and function of peripheral T cells as well as 
increasing the function of B cells, NK cells and macrophages. 
It is well known that the IGF-1 level decreases with age, 
so future trials could be warranted to establish whether its 
supplementation or increase through other hormones (ie, 
growth hormones) would be an effective restorative strat-
egy (Bonkowski et al 2006). However, the potentially toxic 
effects including glucose intolerance, edema, and arthralgia 
may limit this approach.
Dehydroepiandrosterone (DHEA) has been considered 
for immunorestoration, because it dramatically decreases 
with age in both sexes. The direct action of DHEA is still 
questionable as no speciﬁ  c receptor has been identiﬁ  ed. It 
seems that it acts by its intracrinologic transformation to sex 
steroids (Labrie et al 2000). Nevertheless, DHEA has been 
shown to increase IL-2 production and NK cell activity and 
to decrease circulating IL-6 levels (Suzuki et al 1991; Gordon 
et al 2001). These effects can be highly beneﬁ  cial in elderly 
individuals, but no consistent in vivo data on immune effects 
of DHEA supplementation in healthy elderly humans have 
been reported. DHEA has been suggested to be able to an-
tagonize many of the immunosuppressing effects of cortisol 
(Rook et al 1994). Thus the administration of DHEA for 
immunorestoration is still hazardous and needs more well-
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Other hormones with immune regulatory effects includ-
ing melatonin, growth hormone, and IGF-1 have various 
but controversial effects on the aging immune system. The 
hormone-like vitamin, vitamin D (1,25(OH)2D3), may also 
be included in this group: it has been suggested that it could 
intervene in the interaction between APCs and T cells, and 
as such modulate T cell activation (Hewison et al 2003). 
Vitamin D insufficiency, a common problem in appar-
ently healthy elderly people, could lead to the disruption 
of immune tolerance and play a role in the development of 
chronic inﬂ  ammatory disease and the autoimmune disorders 
often seen with aging. This could be related to the failed up-
regulation of T regulatory cells for suppressing autoreactive 
T cells (Adorini 2003). As most elderly people nowadays 
are under Vitamin D treatment for osteoporosis, it would 
be worth evaluating the long-term effects of this therapy 
on immunity.
Strategies to reduce the infectious 
antigenic load
In this context it is not only vital to recognize the role of 
acute infections that can further exhaust a declining immune 
system, and attempt to reduce them by vaccination strategies. 
It could be even more important to recognize the existence of 
chronic latent infections, mainly Herpes viruses, providing a 
continuous antigenic load and chronic stimulation resulting 
in exhaustion of the T cells involved (Pawelec et al 2004). 
Not only persistent viruses, but also the presence of sub-
clinical bacterial infections might also contribute to chronic 
antigenic stress, as well as the tumors that are probably very 
common but not clinically dominant in the majority of the 
elderly. Thus, strategies combating these sources of chronic 
stimulation could have a general immunorestorative role on 
age-associated immune dysfunction.
Vaccinations are critically important to maintain good 
health in the elderly, in the face of their declining immune 
competence. Even in the immunocompromised elderly, vac-
cinations can be beneﬁ  cial in preventing pneumococcal pneu-
monia, inﬂ  uenza, and tetanus. The elderly may not achieve 
an adequate antibody response, but most are able to mount 
some level of response (McElhaney 2005). The problem with 
the present form of conventional split or subunit vaccines 
is that they are not optimal for stimulation of cell-mediated 
immunity, in particular, CTL activity. There is an ongoing 
research effort to develop strategies for enhancing antibody 
production in the elderly by vaccines targeting both the 
humoral and the cellular immune response. New strategies 
seem to be promising, mainly virosomal vaccines tested pri-
marily for inﬂ  uenza so far. Virosomes are lipid-based antigen 
delivery systems using phospholipids to build reconstituted 
virus envelopes which can be used for vaccination, closely 
mimicking the natural virus (Huckriede et al 2005). Thus, 
functionally reconstituted influenza virosomes preserve 
the receptor binding and membrane fusion activity of 
the viral hemagglutinin. Because virosomes lack viral 
RNA, binding and fusion to cells does not result in their 
infection. Virosomes are able to activate the humoral and 
the cellular immune system with great efficacy (Bayes et 
al 2006). Furthermore, the incorporation of lipopeptide 
adjuvant activating TLRs would be of great usefulness 
as in this way DC activation can be controlled via the 
induced cytokine profile and respectively the nature 
and the magnitude of the adaptive immune response. 
Virosomal influenza vaccine has been shown to confer a 
high degree of serological protection in healthy elderly 
subjects and subjects at risk for influenza with low pre-
vaccination antibody titers, comparable with protection 
in young adults (De Bruijn et al 2004).
The combination of improved vaccines, such as described 
above, with immuno-enhancing agents could be of further 
beneﬁ  t in the elderly. In this context, mainly the use of IL-2 
and IL-7 has been considered (Sin et al 2000). IL-7 could 
increase the maintenance or even expansion of effector 
memory helper T cells responding to inﬂ  uenza. General 
adjuvants have also been used for many years, such as the 
alum-based human vaccines (Cox and Coulter 1997). How-
ever, the adjuvant properties of alum are only minimally 
effective in elderly compared with young subjects. Therefore 
there is a great need to develop more effective adjuvants. In 
an aged mouse model, prokaryotic DNA containing unmeth-
ylated cytidine phosphate guanosine (CpG) motifs yielded 
strong enhancement of the immunization effects of hepatitis 
B vaccine (Qin et al 2004). 
An increased frequency of re-vaccination has also been 
suggested as a way of improving outcome in the elderly, 
eg, for tetanus (McElhaney 2005). Moreover, in the future 
it can be imagined that a vaccine could be developed against 
chronic, nondirectly lethal viral infections which can cause 
persisting antigenic stimulation, thereby exhausting the 
immune repertoire. These viruses are mainly the CMV, 
HSV, EBV and to lesser extent in the elderly perhaps HIV. 
The possibility of using these vaccines would dramatically 
increase the immunocompetence of elderly subjects mainly 
if we consider the “infectious nature” of immunosenescence Clinical Interventions in Aging 2007:2(1) 48
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as discussed above (Koch et al 2006). At this moment there 
is no major viable anti-CMV vaccine (Pawelec, Koch, Gout-
tefangeas, et al. 2006). However, Oxman and colleagues 
(2005) published a large clinical trial on the utilization of a 
vaccine to prevent Herpes Zoster and post-herpetic neural-
gia in older adults. This is not a vaccine aimed to eradicate 
the latent herpes zoster (VZV) infection but to signiﬁ  cantly 
decrease VZV clinical infections. The effectiveness of 
the high potency Oka vaccine probably results from the 
restoration to some extent of VZV-specific T cells to a 
level above the threshold for herpes zoster clinical mani-
festations either by reversing a gradual decline from the 
original expansion of VZV-specific memory T cells or by 
substituting immunization for exogenous or endogenous 
re-exposures that could boost immunity (Arvin 2006). 
This implies that immunization against VZV, even if it 
cannot boost the immune system sufficiently to eradi-
cate the virus, could still be strong enough to enhance 
acquired immunity to control the clinical manifestations 
of a persistent pathogen. This could, however, diminish 
the immune system-exhausting effect of this persistent 
virus. This could open new avenues for other types of 
vaccination against latent immunosuppressing viruses. 
Finally, the reduction of the viral load, as in HIV infec-
tions as well as in herpes zoster, can be used. The newer 
generations of antiviral drugs could be used with an ac-
ceptable safety profile in the elderly, such as acyclovir 
and famcyclovir (Scheinfeld 2005). These agents could 
reduce viral load and extend the time to exhaustion for 
viral antigen-specific T cells. 
Identification and treatment of subclinical infections 
could be valuable targets for clinical interventions with 
beneficial effects on immunity as well, for example, the 
very common urinary tract infections in the elderly. The 
search for and eradication of these continuous sources 
of antigenic stimulation could also have an impact on 
immune response maintenance with aging. The same 
argument regarding occult sources of antigen applies to 
tumors, which, while being immunogenic, remain indo-
lent in the elderly. 
Restoration of the thymus
The rejuvenation of a functional thymus is likely to be 
another necessity for maintaining or restoring effective 
immunity with ageing. This would require that thymic 
activity is increased without compromising positive and 
negative thymic selection and that the newly produced 
naïve thymic cells are released to the periphery (and not 
stopped by homeostatic feedback from a “full” periphery). 
Several possibilities can be envisaged to help to maintain 
the function of the thymus (Sutherland et al 2005). The ﬁ  rst 
is physical grafting of functionally intact thymus to old 
subjects but this approach clearly has ethical and logistic 
problems in elderly people. However, transplantation of 
cultured thymic fragments to neonatal patients with 
DiGeorge syndrome has been quite successful (Markert 
et al 1999). Second, rapidly progressing stem cell research 
could also eventually result in the generation of thymic 
epithelial progenitor cells for reconstitution. Third, the 
use of IL-7 has been explored. IL-7 is a cytokine playing 
a crucial role in the development and maintenance of the 
peripheral T cell pool. Thymus IL-7 content decreases 
with age, leading to decreased thymic output of naïve 
cells. This was the rationale for treatment strategies ad-
ministering IL-7, which induced some degree of thymic 
rejuvenation in mice (Aspinall 2006). There are currently 
many unresolved questions on IL-7 therapy before it could 
be used in elderly humans, ﬁ  rst and foremost being the 
lymphoma genesis seen in mice. This could be overcome 
by more efﬁ  cient targeting of the cytokine to the thymus, 
rather than systemically using high doses. Thus, the ad-
vance of gene therapy designing vectors speciﬁ  c for the 
thymus would be a major breakthrough in the thymus 
rejuvenation trials.
Antiinﬂ  ammatory agents
As discussed above, aging is accompanied by low grade 
inﬂ  ammation, held responsible for many of the patholo-
gies developing in the elderly and termed “Inﬂ  amm-aging” 
(Franceschi et al 2000b). There is an unbalance between the 
functioning of the innate and the adaptive immune systems 
manifested by the increase of soluble mediators of Th1 type 
such as IL-6, TNF-α, and IL-1. In several autoimmune diseases 
such as rheumatoid arthritis (RA) or multiple sclerosis (MS), 
blocking antibodies and soluble receptors specific for 
inﬂ  ammatory cytokines such TNF-α have had notable 
therapeutic efﬁ  cacy (Owens 2002). Thus, the age-associ-
ated increase in proinﬂ  ammatory cytokines and increased 
autoimmune disease in the elderly, raise the possibility that 
some sort of proinﬂ  ammatory cytokine blocking antibodies 
or soluble receptors could also be beneﬁ  cial for the elderly. 
Here, anti-TNF-α, anti-IL-1, anti-IL-6, and anti-IL-15 
chimerized monoclonal antibodies could be applied. Soluble 
recombinant cytokine receptor-Ig fusion proteins could be Clinical Interventions in Aging 2007:2(1) 49
Immunosupportive therapies in aging
also useful. However, there are clear drawbacks to general 
antiinﬂ  ammatory therapy, as this response is appropriate at 
times; indeed, in cardiac disease and sepsis their use was 
detrimental, and they could also increase the susceptibility 
of individuals to some infections such as tuberculosis. 
There are other less potent well-known inflamma-
tion-modulating drugs that have few side effects and 
can be used with safety even in very old subjects. Such 
drugs include statins, and NSAIDs. These are pleitropic 
drugs having multiple targets in the inflammatory re-
sponse. They could act in preventing several age-related 
immune-associated diseases such as atherosclerosis, 
dementia, and sarcopenia. Large longitudinal studies 
were already conducted and prove the beneficial effect 
of such drugs (Foody et al 2006). The statins developed 
and used primarily for atherosclerosis prevention and 
treatment have also shown significant beneficial effects 
on susceptibility to a wide variety of cancers (Pahan 
2006). There are several other drugs which could have 
anti-inflammatory effects, such as those targeting either 
the selectins (pan-selectin inhibitors), TLR, the NF-κB 
pathway by inhibiting inhibitor κB kinase (IKK) activa-
tion, or the matrix metalloproteinases (MMPs). These 
strategies would not aim to completely restore the altered 
immune response with aging but could attenuate some of 
the consequences due to the low grade inflammation and 
its clinical sequele.
Modulating telomere loss: Expression
of the catalytic component of telomerase
CD8+ T cells show the greatest telomere length erosion, a 
sign of proliferation due to chronic antigenic stimulation 
(Effros 2004). It is tempting to suggest interventions aimed 
at restoring the telomere repeats. An obvious approach 
could be telomerase gene therapy. However, there are 
multiple problems with this approach including eventual 
carcinogenesis. A possibly safer target of intervention could 
be the repression of telomere binding protein (TRF1). This 
has not yet been sufﬁ  ciently explored for use in therapy. It 
is also conceivable that the erosion of telomeres could be 
prevented in the ﬁ  rst place. Some data using antioxidants 
suggest that this might be possible even after several cell 
division cycles (Zhang et al 2002). Vaccination to decrease 
chronic viral load exhausting the immune system would be 
also beneﬁ  cial for telomere length maintenance. Thus, an 
effective approach to diminish telomere loss would be of 
great importance to avoid the accumulation of replicative 
senescent T cells with aging.
In vitro expansion of immunocompetent 
T cells and their reintroduction 
in the aging organism
T cells of patients with immune deﬁ  ciency cannot efﬁ  ciently 
proliferate in vivo by the usual antigenic stimulation. These 
T cells, however, can be expanded in vitro efﬁ  ciently in the 
presence of immobilized anti-CD3 Ab and IL-2. The ideal 
T cells for in vitro expansion are obtained and stored in liquid 
nitrogen, when individuals are young and healthy. When 
individuals need immunocompetent T cells in later life, the 
frozen T cells can be thawed and expanded in vitro 500- to 
1000-fold or more. Roughly speaking, 1 × 1010 T cells can 
be obtained from 20 ml of peripheral blood, stored in liquid 
nitrogen. These autologous activated T cells propagated in 
vitro could be infused into patients or frail elderly people 
and immunological restoration can be expected. A recent 
paper reported that immunotherapy with activated T cells 
propagated in this way did not enhance or promote autoim-
mune phenomena (Yamaguchi et al 2004). This procedure 
could be very promising however clearly more research is 
needed before its routine clinical use.
Modulation of the glycosylation
of membrane proteins
As previously mentioned, the group led by Miller (Garcia 
and Miller 2003; Garcia et al 2005) has shown a deleterious 
role of glycosylated membrane proteins including CD43 in 
CD4+ T cells of old animals. They have also shown that the 
function of mouse CD4+ T cells can be augmented by treat-
ment with an enzyme, O-sialoglycoprotein endopeptidase 
(OSGE), which cleaves surface CD43, suggesting the idea 
that the high levels of glycosylated CD43 found on T cells 
from aged mice may contribute to immunosenescence. 
Recently they have also obtained data to support the notion 
that glycosylated surface proteins hinder CD8 T cell activa-
tion and function in both young and old mice, and raise the 
possibility of signiﬁ  cantly improving CD8 T cell function 
in older individuals through enzymatic alteration of surface 
glycoproteins (Sadighi et al 2006). New results from the same 
group (Berger et al 2006) now show that OSGE improves 
T cell function even in mice lacking CD43, indicating that 
other glycoproteins must contribute to the OSGE effect 
on function. Modulation of the glycosylation status of the Clinical Interventions in Aging 2007:2(1) 50
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membrane proteins participating in T cell activation could 
be another promising new avenue for the modulation of the 
deregulated aging immune system.
Conclusion
There is a large corpus of experimental data suggesting that 
the adaptive immune response, mainly the T cell response, 
is deregulated with aging. Evidence is also accumulating to 
suggest that the innate immune response is altered as well. 
The exact causes of this deregulation are not known but for 
T cells, thymic involution, changes in the distribution of 
subpopulations, and defective T cell signal transduction are 
likely to be major contributors. The latter two alterations 
are likely to be the consequences of T cell clonal exhaus-
tion either by chronic antigenic stimulation or by metabolic 
alterations. It is of note that despite a wealth of data, the 
exact changes in the immune system with aging are still 
controversial because of the confounding inﬂ  uence of the 
physiological aging process and genetic as well as epigenetic 
factors. Thus, the ﬁ  eld urgently needs to agree upon a set of 
biomarkers of immunosenescence to be applied preferably 
in careful longitudinal studies. However, what we do know 
is that the changes in the immune response lead to various 
diseases. The incidence of disease is dramatically increased 
with aging. These diseases are primarily of an infectious 
nature, but probably also include cancer, autoimmunity, and 
chronic inﬂ  ammatory diseases. The deﬁ  nition and clinical 
use of an IRP to predict those at risk of incipient mortality 
could facilitate a major breakthrough in the prevention and 
modulation of immune-related morbidity and mortality. 
Some means to intervene in compensating for immune 
dysregulation which could be applied in the elderly without 
ethical or regulatory problems do already exist. These include 
balanced nutrition in macro and micronutrients, including 
foods such as vegetables and fruit, functional foods such as 
probiotic-containing yoghurt, sustained moderate aerobic 
exercise regimens, and could be relatively easily extended 
to include better vaccination against different pathogens 
especially against inﬂ  uenza, pneumococcus pneumoniae, 
and in the near future against varicella zoster, possibly 
CMV, and possibly application of certain antiviral drugs 
and low-dose cytokines. Nevertheless, there is still a long 
way to go to implement more speciﬁ  c and effective safe 
immunorestorative therapies, even at the level of speciﬁ  c 
nutrients or drugs. Thus, a better understanding of immu-
nosenescence by intensive research and the development of 
new methods and strategies to intervene in its evolution are 
essential for improving the quality of life of the increasingly 
large elderly population. 
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